CureVac N.V. (CVAC)
NASDAQ: CVAC · Real-Time Price · USD
4.410
-0.050 (-1.12%)
At close: Jun 6, 2025, 4:00 PM
4.310
-0.100 (-2.27%)
After-hours: Jun 6, 2025, 7:35 PM EDT

CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of $992.95 million. The enterprise value is $559.59 million.

Market Cap 992.95M
Enterprise Value 559.59M

Important Dates

The last earnings date was Tuesday, May 20, 2025, before market open.

Earnings Date May 20, 2025
Ex-Dividend Date n/a

Share Statistics

CureVac has 225.16 million shares outstanding. The number of shares has increased by 0.20% in one year.

Current Share Class 225.16M
Shares Outstanding 225.16M
Shares Change (YoY) +0.20%
Shares Change (QoQ) +0.31%
Owned by Insiders (%) 5.64%
Owned by Institutions (%) 16.97%
Float 125.70M

Valuation Ratios

The trailing PE ratio is 5.09.

PE Ratio 5.09
Forward PE n/a
PS Ratio 1.75
Forward PS n/a
PB Ratio 1.42
P/TBV Ratio 1.48
P/FCF Ratio 5.91
P/OCF Ratio 5.85
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.15, with an EV/FCF ratio of 3.33.

EV / Earnings 2.87
EV / Sales 0.99
EV / EBITDA 2.15
EV / EBIT 2.27
EV / FCF 3.33

Financial Position

The company has a current ratio of 7.65, with a Debt / Equity ratio of 0.06.

Current Ratio 7.65
Quick Ratio 7.33
Debt / Equity 0.06
Debt / EBITDA 0.15
Debt / FCF 0.24
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is 33.04% and return on invested capital (ROIC) is 24.37%.

Return on Equity (ROE) 33.04%
Return on Assets (ROA) 19.93%
Return on Invested Capital (ROIC) 24.37%
Return on Capital Employed (ROCE) 33.54%
Revenue Per Employee $575,829
Profits Per Employee $198,637
Employee Count 983
Asset Turnover 0.73
Inventory Turnover 4.85

Taxes

In the past 12 months, CureVac has paid $30.76 million in taxes.

Income Tax 30.76M
Effective Tax Rate 13.61%

Stock Price Statistics

The stock price has decreased by -2.65% in the last 52 weeks. The beta is 2.49, so CureVac's price volatility has been higher than the market average.

Beta (5Y) 2.49
52-Week Price Change -2.65%
50-Day Moving Average 3.52
200-Day Moving Average 3.26
Relative Strength Index (RSI) 60.06
Average Volume (20 Days) 781,947

Short Selling Information

The latest short interest is 4.89 million, so 2.17% of the outstanding shares have been sold short.

Short Interest 4.89M
Short Previous Month 4.99M
Short % of Shares Out 2.17%
Short % of Float 3.89%
Short Ratio (days to cover) 9.25

Income Statement

In the last 12 months, CureVac had revenue of $566.04 million and earned $195.26 million in profits. Earnings per share was $0.87.

Revenue 566.04M
Gross Profit 495.98M
Operating Income 246.84M
Pretax Income -297.84M
Net Income 195.26M
EBITDA 260.34M
EBIT 246.84M
Earnings Per Share (EPS) $0.87
Full Income Statement

Balance Sheet

The company has $473.77 million in cash and $40.40 million in debt, giving a net cash position of $433.37 million or $1.92 per share.

Cash & Cash Equivalents 473.77M
Total Debt 40.40M
Net Cash 433.37M
Net Cash Per Share $1.92
Equity (Book Value) 698.97M
Book Value Per Share 3.10
Working Capital 440.78M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $169.73 million and capital expenditures -$10.51 million, giving a free cash flow of $167.94 million.

Operating Cash Flow 169.73M
Capital Expenditures -10.51M
Free Cash Flow 167.94M
FCF Per Share $0.75
Full Cash Flow Statement

Margins

Gross margin is 87.62%, with operating and profit margins of 43.61% and 34.50%.

Gross Margin 87.62%
Operating Margin 43.61%
Pretax Margin 39.93%
Profit Margin 34.50%
EBITDA Margin 45.99%
EBIT Margin 43.61%
FCF Margin 29.67%

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -0.20%
Shareholder Yield -0.20%
Earnings Yield 19.66%
FCF Yield 16.91%
Dividend Details

Analyst Forecast

The average price target for CureVac is $11.00, which is 149.43% higher than the current price. The consensus rating is "Strong Buy".

Price Target $11.00
Price Target Difference 149.43%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) -13.85%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

CureVac has an Altman Z-Score of 3.87 and a Piotroski F-Score of 6.

Altman Z-Score 3.87
Piotroski F-Score 6